Vaxcyte, Inc.
MUN:5VA Voorraadrapport
Marktkapitalisatie: €12.1b
Vaxcyte Dividenden en inkoop
Dividend criteriumcontroles 0/6 Vaxcyte heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
-19.0%
Terugkoop Rendement
Totaal aandeelhoudersrendement -19.0% Toekomstig dividendrendement 0% Dividendgroei n/a Volgende betaaldatum dividend n/a Ex-dividenddatum n/a Dividend per aandeel n/a Uitbetalingsratio n/a
Recente updates van dividend en inkoop
Toon alle updates Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
New major risk - Revenue and earnings growth Sep 04 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
Vaxcyte Appoints John Furey to Board of Directors Jul 02 Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Feb 01
Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
New major risk - Shareholder dilution Aug 29
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
High number of new directors Nov 28
High number of new directors Oct 28
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
High number of new directors Jun 07
Stabiliteit en groei van betalingen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van 5VA in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van 5VA zijn gestegen.
Dividendrendement versus markt Vaxcyte Dividendrendement versus markt
Hoe verhoudt 5VA dividendrendement zich tot de markt? Segment Dividendrendement Bedrijf (5VA) n/a Markt onderkant 25% (DE) 1.7% Markt Top 25% (DE) 4.8% Gemiddelde industrie (Biotechs) 1.5% Analist prognose (5VA) (tot 3 jaar) 0%
Opmerkelijk dividend: Het dividendrendement van 5VA kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van 5VA kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio 5VA te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat 5VA geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}